Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.

Rodrigues MS, Reddy MM, Sattler M.

Antioxid Redox Signal. 2008 Oct;10(10):1813-48. doi: 10.1089/ars.2008.2071. Review.

PMID:
18593226
2.

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

Walz C, Sattler M.

Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. Epub 2005 Oct 5. Review.

PMID:
16213151
3.

Molecular biology of chronic myeloid leukemia.

Maru Y.

Int J Hematol. 2001 Apr;73(3):308-22. Review.

PMID:
11345196
4.

Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Tolomeo M, Dieli F, Gebbia N, Simoni D.

Anticancer Agents Med Chem. 2009 Oct;9(8):853-63. Review.

PMID:
19538165
5.

Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.

Ichim CV.

Stem Cells Transl Med. 2014 Apr;3(4):405-15. doi: 10.5966/sctm.2012-0159. Epub 2014 Mar 5. Review.

6.

Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

Sawyers CL.

Semin Hematol. 2001 Jul;38(3 Suppl 8):15-21. Review.

PMID:
11526597
7.

The second generation of BCR-ABL tyrosine kinase inhibitors.

Tauchi T, Ohyashiki K.

Int J Hematol. 2006 May;83(4):294-300. Review.

PMID:
16757427
8.

Molecular mechanisms of transformation by the BCR-ABL oncogene.

Sattler M, Griffin JD.

Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10. Review.

PMID:
12783368
9.
10.

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.

Melo JV, Deininger MW.

Hematol Oncol Clin North Am. 2004 Jun;18(3):545-68, vii-viii. Review.

PMID:
15271392
11.

Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.

Burchert A.

Curr Hematol Malig Rep. 2014 Mar;9(1):9-16. doi: 10.1007/s11899-013-0196-8. Review.

12.

Mechanisms of transformation by the BCR/ABL oncogene.

Sattler M, Griffin JD.

Int J Hematol. 2001 Apr;73(3):278-91. Review.

PMID:
11345193
13.

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS.

Leuk Res. 2010 Oct;34(10):1255-68. doi: 10.1016/j.leukres.2010.04.016. Review.

PMID:
20537386
14.

Targeted drugs in chronic myeloid leukemia.

Gora-Tybor J, Robak T.

Curr Med Chem. 2008;15(29):3036-51. Review.

PMID:
19075651
15.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

17.

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Maekawa T, Ashihara E, Kimura S.

Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. Review.

PMID:
17929114
18.

[Tyrosine kinase inhibitors for the treatment of CML].

Heim D.

Ther Umsch. 2006 Apr;63(4):249-54. Review. German.

PMID:
16689455
19.

Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.

Mughal TI, Goldman JM.

Front Biosci. 2006 Jan 1;11:209-20. Review.

PMID:
16146726
20.

Therapy options in imatinib failures.

Ramirez P, DiPersio JF.

Oncologist. 2008 Apr;13(4):424-34. doi: 10.1634/theoncologist.2007-0170. Review.

Supplemental Content

Support Center